JP2018505681A5 - - Google Patents

Download PDF

Info

Publication number
JP2018505681A5
JP2018505681A5 JP2017541675A JP2017541675A JP2018505681A5 JP 2018505681 A5 JP2018505681 A5 JP 2018505681A5 JP 2017541675 A JP2017541675 A JP 2017541675A JP 2017541675 A JP2017541675 A JP 2017541675A JP 2018505681 A5 JP2018505681 A5 JP 2018505681A5
Authority
JP
Japan
Prior art keywords
binding site
bispecific antibody
antigen binding
antibody
bispecific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017541675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018505681A (ja
JP6970017B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/017141 external-priority patent/WO2016130539A2/en
Publication of JP2018505681A publication Critical patent/JP2018505681A/ja
Publication of JP2018505681A5 publication Critical patent/JP2018505681A5/ja
Application granted granted Critical
Publication of JP6970017B2 publication Critical patent/JP6970017B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017541675A 2015-02-09 2016-02-09 ヒトa33抗原とdota金属複合体に親和性を有する多重特異性抗体及びその使用 Active JP6970017B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562113988P 2015-02-09 2015-02-09
US62/113,988 2015-02-09
PCT/US2016/017141 WO2016130539A2 (en) 2015-02-09 2016-02-09 Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof

Publications (3)

Publication Number Publication Date
JP2018505681A JP2018505681A (ja) 2018-03-01
JP2018505681A5 true JP2018505681A5 (enExample) 2020-06-11
JP6970017B2 JP6970017B2 (ja) 2021-11-24

Family

ID=56614713

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017541675A Active JP6970017B2 (ja) 2015-02-09 2016-02-09 ヒトa33抗原とdota金属複合体に親和性を有する多重特異性抗体及びその使用

Country Status (8)

Country Link
US (3) US10988534B2 (enExample)
EP (1) EP3256164B1 (enExample)
JP (1) JP6970017B2 (enExample)
CN (1) CN107847584B (enExample)
AU (1) AU2016219534B2 (enExample)
ES (1) ES2789573T3 (enExample)
IL (1) IL253871B (enExample)
WO (1) WO2016130539A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11820832B2 (en) 2014-07-25 2023-11-21 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
MX386342B (es) 2014-07-25 2025-03-18 Memorial Sloan Kettering Cancer Center Móleculas de unión a her2 y cd3 biespecíficas.
WO2016130539A2 (en) * 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
US11046768B2 (en) 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
ES3057687T3 (en) 2017-07-06 2026-03-04 Memorial Sloan Kettering Cancer Center Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy
IL273484B2 (en) * 2017-09-23 2025-12-01 Memorial Sloan Kettering Cancer Center A33 antibody compositions and methods of using the same in radioimmunotherapy
CN112088169A (zh) * 2018-03-12 2020-12-15 纪念斯隆凯特琳癌症中心 双特异性结合剂及其用途
KR102884852B1 (ko) * 2018-04-16 2025-11-14 에프. 호프만-라 로슈 아게 킬레이트화된 방사성핵종에 대한 항체
PL3781201T3 (pl) * 2018-04-16 2026-02-23 Orano Med Manufacturing SAS Przeciwciała dla chelatowanych radionuklidów i środków klarujących
EP3958874A4 (en) 2019-04-23 2023-09-06 The Trustees of The University of Pennsylvania DOTA-BINDING CHIMERIC ANTIGEN RECEPTOR FOR CELLULAR THERAPY
WO2021244721A1 (en) 2020-06-04 2021-12-09 Y-Mabs Therapeutics, Inc. Anti-b7h3 antibodies for the treatment of cancer
CA3180690A1 (en) * 2020-06-17 2021-12-23 Ahmed Mahiuddin Cd38 antibodies for treatment of human diseases
WO2022005991A1 (en) * 2020-06-29 2022-01-06 Memorial Sloan Kettering Cancer Center Platform for assessing in vivo and in vitro hapten-capture in a cell bound system
CN116096433A (zh) * 2020-06-29 2023-05-09 纪念斯隆凯特琳癌症中心 表达c825的免疫细胞及其诊断用途
WO2022005996A1 (en) * 2020-06-29 2022-01-06 Memorial Sloan Kettering Cancer Center Systems for in vivo monitoring of immune cells in patients undergoing cellular immunotherapy
US20230365636A1 (en) 2020-11-16 2023-11-16 Technische Universität München Bioorthogonal reporter gene system
AU2021381768A1 (en) * 2020-11-18 2023-06-22 Memorial Sloan Kettering Cancer Center Anti-gpa33 multi-specific antibodies and uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US5851526A (en) 1985-04-19 1998-12-22 Ludwig Institute For Cancer Research Methods of treating colon cancer utilizing tumor-specific antibodies
US6190640B1 (en) 1985-04-19 2001-02-20 Ludwig Institute For Cancer Research Method for treating neoplasia using humanized antibodies which bind to antigen A33
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE68928427T2 (de) 1988-09-15 1998-06-04 Univ Columbia Antikörper mit modifiziertem Kohlenhydratgehalt und Verfahren zur Herstellung und Verwendung
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
ATE182651T1 (de) 1992-06-09 1999-08-15 Hoppe Ag Riegel und türschloss
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5413823A (en) 1994-02-02 1995-05-09 Shippers Paper Products Company Collapsible and expandable roll riser
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5886793A (en) 1995-04-04 1999-03-23 Oki Data Corporation Facsimile machine adapted to reduce risk of data loss
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US6312897B1 (en) 1996-07-03 2001-11-06 President And Fellows Of Harvard College Template-directed interference footprinting of protein-adenine contacts
PT956865E (pt) 1996-08-12 2007-07-30 Mitsubishi Pharma Corp Medicamentos compreendendo inibidores da rho cinase.
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US5955186A (en) 1996-10-15 1999-09-21 Kennametal Inc. Coated cutting insert with A C porosity substrate having non-stratified surface binder enrichment
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6090381A (en) 1997-02-11 2000-07-18 Immunomedics, Inc. Stimulation of an immune response with antibodies labeled with the . .alpha-galactosyl epitope
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6795722B2 (en) 2001-06-18 2004-09-21 Neotech Products, Inc. Electrode sensor package and application to the skin of a newborn or infant
EP1411987A2 (en) * 2001-07-31 2004-04-28 Immunomedics, Inc. Targeted polymeric delivery systems
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US7597876B2 (en) * 2007-01-11 2009-10-06 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
CA2531118C (en) 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
EP2403530B1 (en) * 2009-02-27 2016-05-11 Massachusetts Institute of Technology Engineered proteins with high affinity for dota chelates
US10817851B2 (en) 2009-12-23 2020-10-27 Aristocrat Technologies Australia Pty Limited System and method for cashless gaming
NZ603581A (en) * 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
EP2698431B1 (en) 2011-03-30 2020-09-09 Chugai Seiyaku Kabushiki Kaisha Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
AU2014228772B2 (en) 2013-03-15 2019-02-28 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies
WO2016130539A2 (en) * 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
WO2021133782A1 (en) 2019-12-26 2021-07-01 National Jewish Health Methods of treating cystic fibrosis transmembrane conductance regulator (cftr) dysfunction

Similar Documents

Publication Publication Date Title
TWI821474B (zh) Cd3抗體及其藥物用途
CN112969476B (zh) 多特异性蛋白分子
JP2019535670A5 (enExample)
JP2018504105A5 (enExample)
JP2020534830A5 (enExample)
JP2019527553A5 (enExample)
JP2020503870A5 (enExample)
JP2017114866A5 (enExample)
JP2020525032A5 (enExample)
FI3826667T3 (fi) Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi
JP2012523848A5 (enExample)
JP2015163068A5 (enExample)
JP2013506428A5 (enExample)
JP2018516554A5 (enExample)
JP2023540526A5 (enExample)
JP2012501670A5 (enExample)
JP2018516853A5 (enExample)
JP2013538057A5 (enExample)
RU2020120613A (ru) Антитела, нацеленные на рецептор, связанный с g-белками, и способы их применения
RU2016100892A (ru) Антитела против tweakr и их применение
JP2011207882A5 (enExample)
JP2016516400A5 (enExample)
JP2018530331A5 (enExample)
JP2017521054A5 (enExample)
RU2015142815A (ru) Лечение рака с использованием антител, связывающихся с поверхностным grp78